Antibodies, Monoclonal, Humanized
- Name
- Antibodies, Monoclonal, Humanized
- Accession Number
- DBCAT000014
- Description
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
- Drugs
Drug Drug Description Cetuximab An endothelial growth factor receptor binding fragment used to treat colorectal cancer as well as squamous cell carcinoma of the head and neck. Omalizumab A monoclonal anti-immunoglobulin E antibody used in the treatment of severe asthma and chronic idiopathic urticaria. Adalimumab A monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. Trastuzumab A monoclonal anti-human epidermal growth factor receptor 2 protein antibody used to treat HER2-positive breast, gastroesophageal, and gastric cancers. Natalizumab A monoclonal anti-integrin antibody used to treat Crohn's disease or multiple sclerosis. Palivizumab A monoclonal anti respiratory syncytial virus F protein antibody used to prevent serious sequelae caused by respiratory syncytial virus infection in pediatric patients. Bevacizumab A monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer. Ranibizumab A recombinant humanized monoclonal antibody and VEGF-A antagonist used for the management of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema. Ustekinumab A targeted antibody therapy used to manage inflammatory conditions such as plaque psoriasis, psoriatic arthritis, Crohn's Disease, and ulcerative colitis. Denosumab A RANK ligand (RANKL) inhibitor used for the management of osteoporosis in patients at high risk for bone fractures. Nivolumab A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma. Ipilimumab A human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma. Idarucizumab An antibody that binds dabigatran for the reversal of anticoagulant effects of dabigatran. Atezolizumab A monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy. Ocrelizumab A CD20 specific monoclonal antibody used to treat relapsing remitting multiple sclerosis. Lanadelumab A monoclonal antibody targeted against kallikrein which is used to treat attacks of hereditary angioedema. Galcanezumab A calcitonin-gene related peptide antagonist used to prevent migraines and treat cluster headaches. Ravulizumab A monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis. Risankizumab An interleukin-23 antagonist used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease in adults. Abciximab A monoclonal anti-glycoprotein IIb/IIIa receptor antibody used to prevent thrombosis during percutaneous coronary intervention. Basiliximab A monoclonal anti-C25 antibody (interleukin-2 receptor alpha subunit) used as immunosuppressive therapy in kidney transplant patients. Alemtuzumab A monoclonal anti-CD52 antibody used in the treatment of B-cell chronic lymphocytic leukemia and relapsing forms of multiple sclerosis. Daclizumab A monoclonal anti-CD25 antibody that blocks the interleukin-2 receptor which is used to treat relapsing forms of multiple sclerosis. Panitumumab A recombinant humanized monoclonal antibody used to treat EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens. Trastuzumab emtansine An antineoplastic agent and antibody-drug conjugate used to treat HER2-overexpressing breast cancer. Bevacizumab zirconium Zr-89 Bevacizumab zirconium Zr-89 is under investigation in clinical trial NCT01338090 (89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors). Crizanlizumab A monoclonal antibody that targets selectin to reduce the frequency of vasooclusive crises in patients with sickle cell disease. Enfortumab vedotin An antibody-drug conjugate comprised of a fully human monoclonal antibody and microtubule-disrupting chemotherapeutic agent used in the treatment of advanced or metastatic urothelial cancer. Fremanezumab A humanized monoclonal antibody directed against human calcitonin-gene related peptide to prevent migraines. Satralizumab A subcutaneously injected anti-IL-6 receptor monoclonal antibody for the treatment of neuromyelitis optica spectrum disorder (NMOSD). Odesivimab Part of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells. Maftivimab Part of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells. Atoltivimab Part of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells. Bamlanivimab A neutralizing human IgG1κ monoclonal antibody against the SARS-CoV-2 spike (S) protein for use in patients aged 12 and over at high risk of developing severe COVID-19. Naxitamab A GD2-targeted IgG1 monoclonal antibody for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow. Polatuzumab vedotin A CD79b antibody conjugate indicated to treat different types of large B-cell lymphoma. Abituzumab Abituzumab has been used in trials studying the treatment of Prostate Cancer Metastatic. Belantamab mafodotin An anti B-cell maturation antigen antibody conjugated to a microtubule inhibitor to treat relapsed or refractory multiple myeloma. Cantuzumab ravtansine Investigated for use/treatment in gastric cancer. Cergutuzumab amunaleukin Cergutuzumab amunaleukin is under investigation in clinical trial NCT02004106 (A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors). Certolizumab pegol A tumor necrosis factor (TNF) blocker used to treat a variety of autoimmune and autoinflammatory conditions like Crohn's disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, and plaque psoriasis. Dalotuzumab Dalotuzumab has been investigated for the treatment of Breast Cancer, Non Small Cell Lung Cancer, and Metastatic Colorectal Cancer. Dapirolizumab pegol Dapirolizumab pegol is under investigation in clinical trial NCT02804763 (A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus). Demcizumab Demcizumab is under investigation for the treatment of Nonsquamous Nonsmall Cell Neoplasm of Lung. Depatuxizumab mafodotin No approved indication. Elotuzumab An antineoplastic agent and SLAMF7-directed immunostimulatory antibody used for the treatment of refractory multiple myeloma in combination with other antineoplastic agents. Emibetuzumab Emibetuzumab has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, Hepatocellular Cancer, Gastric Adenocarcinoma, and Non-Small Cell Lung Cancer, among others. Enokizumab Investigated for use/treatment in asthma. Epratuzumab Investigated for use/treatment in leukemia (lymphoid), lymphoma (non-hodgkin's), and systemic lupus erythematosus. Etaracizumab Etaracizumab has been investigated for the treatment of Psoriasis, Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer, and Stage III Renal Cell Cancer. Farletuzumab Investigated for use/treatment in ovarian cancer. Ficlatuzumab Ficlatuzumab has been used in trials studying the treatment of Acute Myeloid Leukemia, Non-small Cell Lung Cancer, Mullerian Mixed Tumor of Ovary, Relapsed Acute Myeloid Leukemia, and Refractory Acute Myeloid... Gemtuzumab ozogamicin A monoclonal anti-CD33 antibody used to treat CD33-positive acute myeloid leukemia. Gevokizumab Gevokizumab has been used in trials studying the treatment of Acne Vulgaris, Osteoarthritis, Behcet's Uveitis, Pyoderma Gangrenosum, and Behcet's Disease Uveitis, among others. Gevokizumab acts as a modulator of cytokine... Gosuranemab Gosuranemab is under investigation in clinical trial NCT02460094 (Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy). Inotuzumab ozogamicin An antibody-drug conjugate used to treat B-cell precursor acute lymphoblastic leukemia (ALL). Ixekizumab A monoclonal antibody used to treat moderate to severe plaque psoriasis. Ladiratuzumab vedotin Ladiratuzumab vedotin is under investigation in clinical trial NCT01969643 (A Safety Study of SGN-LIV1A in Breast Cancer Patients). Lebrikizumab An IgG4 monoclonal antibody against IL-13 used to treat moderate-to-severe atopic dermatitis in adults and adolescents. Lifastuzumab vedotin Lifastuzumab vedotin is under investigation in clinical trial NCT01363947 (Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer). Lintuzumab Lintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia). Lorvotuzumab mertansine Lorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others. Lulizumab pegol Lulizumab pegol is under investigation in clinical trial NCT02843659 (Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome). Margetuximab An Fc-engineered human/mouse chimeric IgG1κ anti-HER2 monoclonal antibody indicated for patients with HER2-positive metastatic breast cancer. Obinutuzumab An antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil. Onartuzumab Onartuzumab has been used in trials studying the treatment of Neoplasms, Lung Cancer, Glioblastoma, Gastric Cancer, and Colorectal Cancer, among others. Oportuzumab monatox Investigated for use/treatment in bladder cancer and head and neck cancer. Otlertuzumab Otlertuzumab is under investigation in clinical trial NCT01188681 (Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia). Ozanezumab Ozanezumab has been used in trials studying the treatment of Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis, Relapsing-Remitting. Pertuzumab An antineoplastic agent used in the treatment of HER2-positive metastatic breast cancer in combination with other antineoplastic agents. Pinatuzumab vedotin Pinatuzumab vedotin is under investigation in clinical trial NCT01691898 (A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With... Ponezumab Ponezumab is under investigation in clinical trial NCT00607308 (A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease). Refanezumab Refanezumab is under investigation in clinical trial NCT00833989 (Safety Escalating Repeat IV, in Stroke Patients). Romosozumab A monoclonal antibody used to treat osteoporosis in postmenopausal women at high risk of fracture, patients who are intolerant of other treatments, or patients who have failed other treatments. Rovalpituzumab tesirine Rovalpituzumab Tesirine has been used in trials studying the treatment of GLIOBLASTOMA, Malignant Melanoma, Other Solid Tumors, Small Cell Lung Cancer, and Medullary Thyroid Cancer, among others. Sacituzumab govitecan Sacituzumab govitecan targets TROP-2-expressing cancer cells through a humanized antibody (RS7) before subsequently becoming internalized and releasing the topoisomerase I inhibitor SN-38 to induce DNA damage-mediated apoptosis. Sibrotuzumab Investigated for use/treatment in cancer/tumors (unspecified), colorectal cancer, and lung cancer. Sofituzumab vedotin Sofituzumab vedotin is under investigation in clinical trial NCT01335958 (Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer). Telisotuzumab vedotin Telisotuzumab vedotin is under investigation in clinical trial NCT02099058 (A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Subjects With Advanced Solid Tumors.). Tildrakizumab An interleukin-23 antagonist used to treat moderate to severe plaque psoriasis. Trastuzumab duocarmazine Trastuzumab duocarmazine is under investigation in clinical trial NCT03262935 (SYD985 vs. Physician's Choice in Participants With Her2-positive Locally Advanced or Metastatic Breast Cancer). Tucotuzumab celmoleukin Tucotuzumab celmoleukin is under investigation in clinical trial NCT00016237 (Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous... Vorsetuzumab mafodotin Vorsetuzumab mafodotin is under investigation in clinical trial NCT01677390 (A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma). Anrukinzumab Anrukinzumab has been used in trials studying the diagnostic of Asthma. Apolizumab Investigated for use/treatment in lymphoma (non-hodgkin's), leukemia (lymphoid), and solid tumors. Bapineuzumab Bapineuzumab has been investigated for the treatment of Alzheimer's Disease. Bemarituzumab Bemarituzumab is under investigation in clinical trial NCT03694522 (A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (Mfolfox6) in Gastric/gastroesophageal Junction Cancer (FIGHT)). Benralizumab A monoclonal antibody used to treat eosinophilic asthma. Bimekizumab An anti-IL-17A, IL-17F, and IL-17AF monoclonal antibody used in the treatment plaque psoriasis. Bivatuzumab Investigated for use/treatment in cancer/tumors (unspecified) and head and neck cancer. Blosozumab Blosozumab has been used in trials studying the basic science and treatment of Osteoporosis and Osteoporosis, Postmenopausal. Bococizumab Bococizumab has been used in trials studying the treatment and prevention of Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, and Heterozygous Familial Hypercholesterolemia. Brolucizumab An anti VEGF-A monoclonal antibody indicated to treat neovascular age related macular degeneration. Brontictuzumab Brontictuzumab has been used in trials studying the treatment of Adenoid Cystic Carcinoma, Relapsed or Refractory Solid Tumors, and Relapsed or Refractory Lymphoid Malignancies. Cabiralizumab Cabiralizumab is under investigation in clinical trial NCT03502330 (APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma). Camrelizumab Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy). Caplacizumab A von Willebrand factor (vWF)-directed antibody fragment used to treat acquired thrombotic thrombocytopenic purpura (aTTP). Clazakizumab Clazakizumab has been used in trials studying the treatment of Rheumatoid Arthritis. Codrituzumab Codrituzumab is under investigation in clinical trial NCT01507168 (A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma). Concizumab Concizumab has been used in trials studying the treatment of Haemophilia A and Congenital Bleeding Disorder. Crenezumab Crenezumab has been used in trials studying the treatment of Alzheimer's Disease. Cusatuzumab A CD70-directed monoclonal antibody under investigation for the treatment of hematological malignancies. Dacetuzumab Investigated for use/treatment in lymphoma (non-hodgkin's) and multiple myeloma. Dezamizumab Dezamizumab is under investigation in clinical trial NCT03417830 (Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging). Domagrozumab Domagrozumab is under investigation in clinical trial NCT01616277 (A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects). Dostarlimab An anti-PD-1 monoclonal antibody used in the treatment of mismatch repair deficient endometrial cancers and solid tumours with no alternative treatment options. Duligotuzumab Duligotuzumab has been used in trials studying the treatment of Neoplasms, Colorectal Cancer, Head and Neck Cancer, and Epithelial Tumors, Malignant. Eculizumab A recombinant humanized monoclonal antibody used to reduce the risk of hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Efalizumab A monoclonal anti-CD11a antibody used to treat moderate to severe plaque psoriasis. Emactuzumab Emactuzumab is under investigation in clinical trial NCT01494688 (A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors). Emicizumab An antibody against Factor IXa and Factor X used to treat hemophilia A. Enoblituzumab Enoblituzumab is under investigation in clinical trial NCT02982941 (Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors). Eptinezumab A monoclonal antibody directed against CGRP infused every 3 months for the preventive treatment of migraine in adults. Etrolizumab A humanized IgG1κ anti-β7 integrin subunit monoclonal antibody under investigation for use in ulcerative colitis and Crohn's disease. Faricimab An IgG1-derived bispecific antibody against VEGF-A and Ang-2 for the treatment of age-related macular degeneration and diabetic macular edema. Flotetuzumab Flotetuzumab is under investigation in clinical trial NCT02152956 (Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS). Fontolizumab Investigated for use/treatment in crohn's disease and psoriasis and psoriatic disorders. Frovocimab Frovocimab is under investigation in clinical trial NCT01671085 (A Study of LY3015014 in Healthy Participants With High Cholesterol). Ibalizumab A CD4-specific antibody used to treat HIV infections. Imgatuzumab Imgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With... Inebilizumab A humanized anti-CD19 cytolytic monoclonal antibody for B-cell depletion in autoimmune conditions. Currently approved only for neuromyelitis optica spectrum disorder (NMOSD). Itolizumab Itolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19). Labetuzumab Labetuzumab is a humanized monoclonal antibody used to treat cancer. Retrieved from "http://en.wikipedia.org/wiki/Labetuzumab" Lacnotuzumab Lacnotuzumab is under investigation in clinical trial NCT01643850 (MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)). Lampalizumab Lampalizumab has been used in trials studying the treatment of Geographic Atrophy. Landogrozumab Landogrozumab has been used in trials studying the treatment of Advanced Cancer, Muscular Atrophy, and Pancreatic Cancer. Leronlimab A humanized monoclonal antibody being investigated Ligelizumab An IgE-directed monoclonal antibody under investigation for the treatment of chronic spontaneous urticaria (CSU). Lumretuzumab Lumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small Cell Lung Cancer, and Non-Squamous Non-Small Cell Lung Cancer. Lutikizumab Lutikizumab is under investigation in clinical trial NCT02087904 (A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis). Matuzumab Investigated for use/treatment in cervical dysplasia/cancer, colorectal cancer, gastric cancer, and lung cancer. Mepolizumab A fully-humanized monoclonal IgG1 kappa anti-IL-5 antibody used in conjunction with other therapies to treat severe asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome. Milatuzumab Milatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), GVHD (Acute or Chronic), Myelodysplastic Syndrome, and Chronic Lymphocytic Leukemia, among others. Mirikizumab An anti-IL-23 monoclonal antibody used as a second-line therapy for moderate-to-severe active ulcerative colitis. Mogamulizumab A monoclonal antibody used to treat relapsed or refractory mycosis fungoides or Sézary syndrome after attempting one other therapy. Monalizumab Monalizumab has been used in trials studying the treatment of Gynecologic Cancer, Chronic Lymphocytic Leukemia, and Squamous Cell Carcinoma of the Oral Cavity. Mosunetuzumab A humanized anti-CD20/CD3 bispecific antibody used to treat relapsed or refractory follicular lymphoma. Motavizumab Investigated for use/treatment in viral infection and pediatric indications. Nemolizumab Nemolizumab is under investigation in clinical trial NCT03921411 (A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Subjects With Atopic Dermatitis (AD)). Nimotuzumab An EGFR-targeting monoclonal antibody used in the treatment of squamous cell carcinomas of the head and neck and glioblastomas. Olendalizumab Olendalizumab is under investigation in clinical trial NCT01883544 (Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects). Olokizumab A humanized anti-IL-6 IgG4κ antibody under investigation for use in autoimmune conditions including rheumatoid arthritis. Ozoralizumab Ozoralizumab has been used in trials studying the treatment of Rheumatoid Arthritis and Active Rheumatoid Arthritis. Parsatuzumab Parsatuzumab is under investigation in clinical trial NCT01366131 (Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous... Pascolizumab Investigated for use/treatment in asthma. Pateclizumab Pateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in... Pembrolizumab A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma. Pexelizumab For the treatment of inflammation during cardiac surgery. Pidilizumab Pidilizumab is under investigation in clinical trial NCT01952769 (Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma). Plozalizumab Plozalizumab has been investigated for the treatment of Atherosclerosis. Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found on the surface of certain white blood cells including... Vonlerolizumab Vonlerolizumab is under investigation in clinical trial NCT03029832 (A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who... Prasinezumab Prasinezumab is under investigation in clinical trial NCT03100149 (A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease). Quilizumab Quilizumab is under investigation in clinical trial NCT01160861 (A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis). Ravagalimab Ravagalimab is under investigation in clinical trial NCT03695185 (A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe It Is in Participants With Moderate to Severe Ulcerative Colitis... Reslizumab An IL-5 antagonist used as an add-on maintenance treatment of patients with severe eosinophilic asthma in adults. Rontalizumab Rontalizumab has been used in trials studying the treatment of Systemic Lupus Erythematosus. Ruplizumab Investigated for use/treatment in thrombocytopenia, systemic lupus erythematosus, transplant (rejection), blood (blood forming organ disorders, unspecified), and multiple sclerosis. Samalizumab Samalizumab has been used in trials studying the treatment of Multiple Myeloma and B-cell Chronic Lymphocytic Leukemia. Simtuzumab Simtuzumab has been used in trials studying the treatment and basic science of Myelofibrosis, Pancreatic Cancer, Colorectal Cancer, and Idiopathic Pulmonary Fibrosis. Siplizumab Investigated for use/treatment in psoriasis and psoriatic disorders, transplant (rejection), graft versus host disease, lymphoma (unspecified), and leukemia (unspecified). Solanezumab Solanezumab is under investigation for the treatment of Dementia, Alzheimers Disease, and Alzheimers Disease, Familial. Sonepcizumab Investigated for use/treatment in solid tumors. Spartalizumab Spartalizumab is under investigation in clinical trial NCT02605967 (Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma). Talacotuzumab Talacotuzumab is an IgG1 monoclonal antibody directed toward the IL3 receptor α–subunit, also known as CD123. It is under investigation in clinical trial NCT01632852 (A Study of CSL362 in Patients... Tanezumab Tanezumab has been investigated for the treatment of Osteoarthritis, Knee and Neuralgia, Postherpetic. Tefibazumab Tefibazumab is under investigation in clinical trial NCT00198289 (Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs). Telisotuzumab Telisotuzumab is under investigation in clinical trial NCT01472016 (Study of ABT-700 in Subjects With Advanced Solid Tumors). Teplizumab A CD3-directed monoclonal antibody indicated to delay the onset of Stage 3 type 1 diabetes in patients with Stage 2 type 1 diabetes. Tibulizumab Tibulizumab is under investigation in clinical trial NCT03736772 (A Study of LY3090106 in Japanese and Caucasian Healthy Participants). Tigatuzumab Tigatuzumab is under investigation in clinical trial NCT00991796 (CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)). Tislelizumab An IgG4 variant monoclonal antibody against PD-1 indicated for the treatment of unresectable, locally advanced or metastatic esophageal squamous cell carcinoma Tocilizumab An interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA). Tomuzotuximab Tomuzotuximab is under investigation in clinical trial NCT02052960 (CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer). Toralizumab Toralizumab is under investigation in clinical trial NCT03605927 (CD40-L Blockade for Prevention of Acute Graft-versus-host Disease). Tregalizumab Tregalizumab has been used in trials studying the treatment of Rheumatoid Arthritis. Vanucizumab Vanucizumab has been used in trials studying the treatment of ColoRectal Cancer and Advanced/Metastatic Solid Tumors. Vatelizumab Vatelizumab has been used in trials studying the treatment of Ulcerative Colitis. Vedolizumab An integrin blocker and anti-inflammatory agent used to manage ulcerative colitis and Crohn's disease in adults. Veltuzumab Investigated for use/treatment in lymphoma (non-hodgkin's). Visilizumab Visilizumab has been investigated for the treatment of Ulcerative Colitis. Vobarilizumab Vobarilizumab is under investigation in clinical trial NCT02101073 (ALX-0061 Phase I Bioavailability Study in Healthy Volunteers). Vopratelimab Vopratelimab is under investigation in clinical trial NCT02904226 (JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors). Vunakizumab Vunakizumab is under investigation in clinical trial NCT03463187 (Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis). Xentuzumab Xentuzumab is under investigation in clinical trial NCT02191891 (Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)). Zenocutuzumab Zenocutuzumab is under investigation in clinical trial NCT03321981 (MCLA-128 With Trastuzumab/chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer). Tafasitamab A CD19-directed cytolytic monoclonal antibody used in the treatment of B-cell malignancies. Brentuximab vedotin A CD30-directed antibody-drug conjugate used to treat various types of lymphoma. Trastuzumab deruxtecan An antibody used to treat certain types of unresectable or metastatic HER2 positive breast cancer. Spesolimab An interleukin-36 receptor antagonist used to treat generalized pustular psoriasis flares in adults. Retifanlimab A PD-1–blocking antibody indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma. Epcoritamab A bispecific CD20-directed CD3 T-cell engager used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults. Ramucirumab An antineoplastic agent and direct VEGFR2 (vascular endothelial growth factor receptor 2) antagonist that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis and enhance tumor blood supply. - Drugs & Drug Targets